GlycoMimetics Announces Its Addition to the Russell Microcap® Index
26 6월 2023 - 9:00PM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage
biotechnology company discovering and developing glycobiology-based
therapies for cancers and inflammatory diseases, today announced
that it is set to join the Russell Microcap Index at the conclusion
of the 2023 Russell indexes annual reconstitution, effective after
the U.S. market opens on June 26, 2023.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $18 trillion in assets
are currently benchmarked against Russell’s US indexes. Russell
indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap Index and the
Russell indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company
discovering and developing glycobiology-based therapies for
cancers, including Acute Myeloid Leukemia, and for inflammatory
diseases with high unmet needs. The company’s science is based on
an understanding of the role that carbohydrates play in cell
recognition. Its specialized chemistry platform is deployed to
discover small molecule drugs--known as glycomimetics—that alter
carbohydrate-mediated recognition in diverse disease states. As a
leader in this science, GlycoMimetics leverages its unique approach
to advance a pipeline of wholly-owned drug candidates with the goal
of developing transformative therapies for diseases with high unmet
need. GlycoMimetics is headquartered in Rockville, MD in the
BioHealth Capital Region. Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. Actual
results may differ materially from those described in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the
Company’s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on March 29, 2023, and other filings
GlycoMimetics makes with the SEC from time to time. Forward-looking
statements speak only as of the date of this release, and
GlycoMimetics undertakes no obligation to update or revise these
statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230626407766/en/
Investors: Argot Partners Leo Vartorella 212-600-1902
Glycomimetics@argotpartners.com
Media: Geoff Cook 973-652-7927
GlycoMimetics (NASDAQ:GLYC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GlycoMimetics (NASDAQ:GLYC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024